Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Testing for Solid Organ Allograft Rejection | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Transurethral Waterjet Ablation of the Prostate | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Genetic Testing for Heritable Thoracic Aortic Disease | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Genetic Testing for Heritable Thoracic Aortic Disease | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Total Joint Arthroplasty | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Botulinum Toxin Injections | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Micro-Invasive Glaucoma Surgery (MIGS) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Cataract Surgery | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Cervical Fusion | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Trigger Point Injections | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Intraarticular Knee Injections of Hyaluronan | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Sacroiliac Joint Injections and Procedures | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Epidural Steroid Injections for Pain Management | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Cosmetic and Reconstructive Surgery | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Facet Joint Interventions for Pain Management | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Colon Capsule Endoscopy (CCE) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Minimal Residual Disease Testing for Cancer | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Implantable Continuous Glucose Monitors (I-CGM) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Transurethral Waterjet Ablation of the Prostate | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDx: Molecular Testing for Solid Organ Allograft Rejection | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Blood Product Molecular Antigen Typing | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Pharmacogenomics Testing | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | MolDX: Repeat Germline Testing | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) | Criteria changed |
| May 17, 2026 | WPS Government Health Administrators | Corneal Hysteresis | Criteria changed |